<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0001677'>Coronary artery disease</z:hpo> is the most important cause of mortality in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to determine the prevalence of silent <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischemia</z:e> (SMI) and the effect of <z:chebi fb="0" ids="35664">statin</z:chebi> therapy on SMI in type 2 diabetic patients without manifest <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: A randomized, placebo-controlled, double-blind trial was performed in 250 patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> without manifest <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were given either 0.4 mg cerivastatin or placebo daily </plain></SENT>
<SENT sid="4" pm="."><plain>In August 2001, when cerivastatin was withdrawn from the market, cerivastatin 0.4 mg was replaced by 20 mg <z:chebi fb="0" ids="9150">simvastatin</z:chebi> without deblinding the study </plain></SENT>
<SENT sid="5" pm="."><plain>The primary end point was the change in ischemic episodes, duration, and burden as measured by 48-h ambulatory electrocardiography (AECG) over 2 years </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: At baseline, 47 of 233 (20%) evaluable ambulatory electrocardiograms showed evidence of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>After 2 years, there was a trend toward more <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in both treatment groups, without significant differences between the changes in ischemic parameters (episodes P = 0.498; duration P = 0.697; burden P = 0.798) in the two treatment groups </plain></SENT>
<SENT sid="8" pm="."><plain>Cardiovascular events occurred in 12 patients in the placebo group and in two patients in the <z:chebi fb="0" ids="35664">statin</z:chebi> group (P = 0.006) </plain></SENT>
<SENT sid="9" pm="."><plain>There was no relationship between these cardiovascular events and the presence of SMI at baseline </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: SMI occurred in 20% of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients without manifest <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>There was no effect from 2 years of <z:chebi fb="0" ids="35664">statin</z:chebi> therapy on SMI </plain></SENT>
<SENT sid="12" pm="."><plain>In contrast, we observed a significantly lower cardiovascular event rate on <z:chebi fb="0" ids="35664">statin</z:chebi> therapy </plain></SENT>
<SENT sid="13" pm="."><plain>AECG may not be a proper tool for risk stratification in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>